Year: 2015
Type: editorial
Abstract: Noninvasive molecular biomarkers are becoming attractive tools to monitor disease progression, aid drug development programs and use as surrogate outcome measures in clinical trials. Cutting edge proteomic methods to assay biomarkers in body fluids have been developed in the past few years, but transitioning them to clinical practice has been slow and depends on the qualification of both the method and the biomarker.
Source: Expert Review of Proteomics
Author: Yetrib Hathout
Institution: Children's National
Language: English
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: bronze
Funder: National Institutes of Health
OpenAlex ID: W2155145689
